Curie Bio
SlowingFiled to raiseCambridge, MABiotechnology, Pharmaceuticals, HealthcareLast fund filed 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Curie Bio Seed Fund II-A | February 2025 | $5.7M | $5.7M | 40 |
| Curie Bio Seed Fund II | 2025 | $342M | $342M | 46 |
| Curie Bio Series A Fund I | February 2024 | $377M | $377M | 48 |
| Curie Bio Series A Fund I-AFiled to raise in 2024, with no closing reported yet. | 2024 | $5M | $0 | 0 |
| Curie Bio Seed Fund IFiled to raise in 2022, with no closing reported yet. | 2022 | $275M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Alexis Borisy | Slowing | Biotech & pharma | 9 | 1 |
| Zachary Weinberg | Quiet | Digital health | 1 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Curie Bio’s own portfolio companies, based on 8 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Curie Bio’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Third Rock Ventures | 4 | Blueprint Medicines, Celsius Therapeutics, Revolution Medicines, Tango Therapeutics |
| Atlas Venture | 2 | Editas Medicine, Magenta Therapeutics |
| Bain Capital Life Sciences | 1 | Editas Medicine |
| Biomatics Capital Partners | 1 | Editas Medicine |
A shared board seat: a company where filings name a Curie Bio partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.